fedratinib and Pneumonia--Viral

fedratinib has been researched along with Pneumonia--Viral* in 1 studies

Other Studies

1 other study(ies) available for fedratinib and Pneumonia--Viral

Article	Year
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3 COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles. Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Cytokines; Humans; Janus Kinase 2; Pandemics; Pneumonia, Viral; Pyrrolidines; SARS-CoV-2; Sulfonamides; Th17 Cells	2020

Article

Year

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020, Volume: 53, Issue:3

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.

Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Cytokines; Humans; Janus Kinase 2; Pandemics; Pneumonia, Viral; Pyrrolidines; SARS-CoV-2; Sulfonamides; Th17 Cells

2020